pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,505 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1888Endpoints1465Fierce Biotech779BioSpace767BioPharma Dive555raps254onclive165fda recalls
therapy area
allOncology13094Rare Disease3386Immunology3069Cardiology2866Hematology2335Pulmonology2299Vaccines
  • FDA approves Regeneron's siRNA drug Livsayis for myasthenia gravis, expanding its neurology portfolio
    Regeneron has received FDA clearance for its siRNA‑based therapy cemdisiran, now marketed as Livsayis, to treat myasthenia gravis. This approval is the second new myasthenia gravis drug cleared by…
    Endpoints · 1d agoApprovalPositive↗ source
  • Isomorphic Labs partners with Merck on AI-driven oncology drug discovery after $5 billion funding round
    Isomorphic Labs announced a new collaboration with Merck & Co., adding the pharma giant to its AI drug discovery partners. The agreement follows Isomorphic's recent $5 billion financing and will f…
    Fierce Biotech · 1d agoDealPositive↗ source
← prev
page 2 of 141
next →
123
fda medwatch117
globenewswire health73
fda press62
1882
Psychiatry & CNS1247
Ophthalmology1150
Endocrinology & Metabolism809
Pain801
Nephrology789
  • AbbVie signs up to $2.5 B licensing deal with DISCO to develop solid tumor bispecific therapies
    AbbVie announced a licensing agreement with European biotech DISCO Pharmaceuticals that could be worth as much as $2.5 billion. The deal includes a $40 million upfront payment and future milestones…
    BioSpace · 1d agoDealPositive↗ source
  • AbbVie partners with Disco Pharmaceuticals on up to $2.5 billion solid tumor deal
    AbbVie announced a partnership with Disco Pharmaceuticals, a preclinical cancer biotech based in Cologne, Germany, to advance antibody‑drug conjugate and T cell engager programs targeting solid tum…
    Endpoints · 1d agoDealPositive↗ source
  • Novartis CEO says shareholders remain supportive despite recent trial setbacks
    Novartis chief executive Vas Narasimhan told Fierce that, despite a series of recent clinical setbacks, most shareholders continue to back the company’s long-term strategy. The setbacks include th…
    Fierce Biotech · 1d agoPositive↗ source
  • Eli Lilly breaks ground on $3.5 billion Pennsylvania plant to produce obesity drugs
    Eli Lilly has begun construction of a new manufacturing facility in the Lehigh Valley region of Pennsylvania. The $3.5 billion plant is slated to increase capacity for the company’s obesity drug po…
    Endpoints · 1d agoNeutral↗ source
  • Chinese AI lab MegaRobo secures almost $200 million in funding as Isomorphic strikes partnership with Merck
    Chinese AI and lab-automation company MegaRobo announced it has raised close to $200 million, according to a post on WeChat. The capital injection is intended to expand the firm’s artificial-intel…
    Endpoints · 1d agoDealPositive↗ source
  • Novartis forecasts modest 5% growth, bets on pipeline as Kisqali loses patent
    Novartis told investors it expects slower top‑line growth, narrowing its sales guidance to about 5% annual increase through 2031 as the breast‑cancer drug Kisqali faces patent expiry and price pres…
    BioSpace · 1d agoNeutral↗ source
  • Oura announces acquisition of Counsel Health at HLTH conference
    Oura, known for its wearable health tracker, disclosed that it is purchasing Counsel Health, a company that provides health data services. The announcement was made during the HLTH conference, whe…
    Endpoints · 1d agoDealPositive↗ source
  • Teva R&D chief Eric Hughes resigns, company taps innovative medicines head as interim lead
    Teva announced that its chief scientific officer for research and development, Eric Hughes, M.D., Ph.D., will leave the company. Hughes, who joined Teva in 2022 as executive vice president of globa…
    Fierce Biotech · 1d agoNegative↗ source
  • Novartis reports mid-stage eczema drug success, plans to restart autoimmune CAR-T trials and narrows sales growth outlook
    Novartis said its experimental eczema treatment achieved a positive result in a mid-stage study, marking the company's first major clinical milestone in the skin-disorder area this year. The compa…
    Endpoints · 1d agoPositive readoutNeutral↗ source
  • nChroma Bio cuts workforce by half and stops HBV cure trial
    nChroma Bio, a Boston biotech focused on epigenetic therapies, announced it is reducing its staff by roughly half. The reduction follows the decision to halt enrollment in its phase 1/2 study of C…
    Fierce Biotech · 1d agoLayoffsNegative↗ source
  • Grand Strand Sandwich Co. recalls four Lunch Box sandwich products over Listeria risk
    Grand Strand Sandwich Company Inc. announced a recall of four Lunch Box sandwich items because they may be contaminated with Listeria monocytogenes. The recalled products are the Chicken Sausage B…
    fda recalls · 1d agoCRLNegative↗ source
  • Nine California biotech firms slash at least half of their workforces amid statewide cuts
    Workforce reductions have affected more than 1,000 biopharma employees in California so far this year, with the hardest hits falling on biotech firms. Nine companies have announced plans to cut at…
    BioSpace · 1d agoLayoffsNegative↗ source
  • Outset Medical issues safety alert for Tablo dialysis system power cords overheat risk
    The FDA’s Center for Devices and Radiological Health has posted an Early Alert after learning that certain power cords used with Outset Medical’s Tablo hemodialysis consoles and the TabloCart with…
    fda medwatch · 1d agoRegulatoryNeutral↗ source
  • Ridley Block Operations recalls Crystalyx HE-20% batch over dangerous urea nitrogen levels in cattle feed
    Ridley Block Operations announced a voluntary recall of one lot of its Crystalyx HE-20% feed after testing revealed elevated non‑protein nitrogen from urea, a condition that can be lethal to cattle…
    fda recalls · 1d agoCRLNegative↗ source
  • Actinogen’s Alzheimer’s drug Xanamem fails pivotal trial, shares plunge over 80%
    Actinogen Medical, an Australian biotech, reported that its only candidate, Xanamem (emestedastat), did not meet the primary endpoint in a Phase 2b/3 study in patients with mild to moderate Alzheim…
    BioSpace · 1d agoNegative readoutNegative↗ source
  • Eli Lilly pilots virtual clinician platform to speed Alzheimer’s diagnosis
    Eli Lilly is testing a new virtual‑clinician service aimed at accelerating the diagnosis and early care for people showing signs of Alzheimer’s disease. The approach allows individuals with memory…
    Endpoints · 1d agoPositive↗ source
  • Evaxion Biotech Shifts R&D Focus Exclusively to Cancer Vaccines, Halts Infectious and Autoimmune Programs
    Evaxion Biotech announced it is ending its infectious disease and autoimmune research programs to concentrate solely on oncology. The company’s most advanced candidate is EVX-01, a therapeutic can…
    Fierce Biotech · 1d agoNeutral↗ source
  • Teva R&D chief Eric Hughes resigns as company pushes innovative medicines expansion
    Teva Pharmaceutical announced that its head of research and development, Eric Hughes, M.D., Ph.D., will resign, with his departure set to occur over the next few months. Hughes joined Teva in 2022…
    Fierce Biotech · 1d agoNeutral↗ source
  • Drugmakers urged to assess device capabilities and engage regulators early for combo products
    At the AFDO/RAPS Combination Products Summit, a panel of experts advised drugmakers that developing standalone medical devices to be used with their drugs requires careful evaluation of the devices…
    raps · 1d agoRegulatoryNeutral↗ source
  • FDA puts drug repurposing front-and-center, says BioSpace podcast
    In a recent episode of BioSpace’s podcast “Denatured,” host Jennifer C. Smith-Parker spoke with Daniel Tillett, chief executive of Racura Oncology, and Sten Sörensen, chief executive of Cereno Scie…
    BioSpace · 1d agoRegulatoryNeutral↗ source
  • Early Alert: B. Braun Medical Inc. Updates Use Instructions for Caresite Micro Luer Access Device
    BBMI corrects Caresite devices due to issue with internal piston remaining depressed following disconnection, preventing the valve from fully closing.
    fda medwatch · 1d agoRegulatoryNeutral↗ source
  • UK MHRA launches AdvanceGxP to help drugmakers address good practice early
    The Medicines and Healthcare products Regulatory Agency in the United Kingdom has introduced a new service called AdvanceGxP. The initiative is designed to give pharmaceutical companies early guida…
    raps · 1d agoRegulatoryNeutral↗ source
  • FDA issues final guidance on 510(k) ownership transfers, shortening sections and adding Q&A
    The U.S. Food and Drug Administration has released a final guidance that spells out the duties of owners of 510(k) clearances when a product is sold or transferred to another company. The new docu…
    raps · 1d agoRegulatoryNeutral↗ source